Natixis Advisors LLC Has $181.33 Million Stake in Boston Scientific Co. (NYSE:BSX)

Natixis Advisors LLC grew its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,030,069 shares of the medical equipment provider's stock after purchasing an additional 184,264 shares during the period. Natixis Advisors LLC owned about 0.14% of Boston Scientific worth $181,326,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BSX. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Boston Scientific by 4.4% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock worth $345,205,000 after acquiring an additional 173,034 shares during the period. Mechanics Bank Trust Department acquired a new stake in Boston Scientific during the 4th quarter worth about $415,000. Highland Capital Management LLC acquired a new stake in Boston Scientific during the 4th quarter worth about $4,887,000. Covenant Asset Management LLC acquired a new stake in Boston Scientific during the 4th quarter worth about $3,405,000. Finally, Brookstone Capital Management boosted its position in Boston Scientific by 23.7% during the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after acquiring an additional 20,307 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on BSX shares. Citigroup raised their price objective on Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Barclays lifted their price target on Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Morgan Stanley lifted their price target on Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Wells Fargo & Company lifted their price target on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, Argus set a $130.00 price target on Boston Scientific in a report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and an average price target of $108.91.

Remove Ads

Boston Scientific Stock Performance

NYSE BSX traded up $0.27 during trading on Tuesday, hitting $99.17. The company's stock had a trading volume of 5,370,015 shares, compared to its average volume of 5,741,505. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a 50 day moving average price of $101.35 and a 200 day moving average price of $92.09. The firm has a market cap of $146.36 billion, a P/E ratio of 79.34, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 52 week low of $66.80 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Daniel J. Brennan sold 67,333 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the sale, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 137,302 shares of company stock worth $14,319,269. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.